Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 30.
doi: 10.1007/s15010-025-02569-x. Online ahead of print.

Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients-a post-hoc analysis of the HYPRESS trial

Caroline Neumann  1 , Margit Leitner  2 , Frank Bloos  2 , Dorothea Lange  3 , Holger Bogatsch  4 , Djillali Annane  5 , Jerôme Fleuriet  5 , Josef Briegel #  3 , Michael Bauer #  2 ; SepNet Critical Care Trials Group; iRECORDS collaborators
Collaborators, Affiliations

Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients-a post-hoc analysis of the HYPRESS trial

Caroline Neumann et al. Infection. .

Abstract

Purpose: Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment.

Methods: We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predictions were determined by Youden's index. Logistic regression was used to assess bio-ADM subgroups and treatment interaction.

Results: Bio-ADM levels differed significantly in patients with or without septic shock within 14 days (p = 0.011). While the area under the ROC curve (AUC) was only 0.603 (CI 0.531-0.676), patient subgrouping using bio-ADM levels showed significantly higher cumulative incidence of septic shock within 14 days in the subgroup of patients with bio-ADM levels ≥ 37 pg/mL (p < 0.001). The odds ratio for the development of septic shock in this group was 4.67 (95% CI 1.53, 20.3, p = 0.016). A bio-ADM cut-off of ≥ 136 pg/mL was predictive for 90-day (OR 8.21, 95% CI 2.46-27.9, p < 0.001) and 180-day mortality (OR 4.87, 95% CI 1.49-16.0, p = 0.008). Hydrocortisone therapy did not reduce the incidence of septic shock (OR 1.59, 95% CI 0.37-8.15, p = 0.54), 90-day (OR 1.53, p = 0.23) or 180-day mortality (OR 1.41, p = 0.25), regardless of bio-ADM stratification (interaction term p = 0.58 for septic shock; p = 0.31 for 90-day mortality; p = 0.51 for 180-day mortality).

Conclusions: Whereas bio-ADM levels are associated with sepsis outcomes, our data do not indicate usefulness of the marker to identify patients potentially benefitting from hydrocortisone therapy.

Keywords: Bio-adrenomedullin; Hydrocortisone; Predictive enrichment; Sepsis; Septic shock.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests. Ethics approval and consent to participate: The study was performed in accordance with the Declaration of Helsinki and has been approved by the ethical committees of the participating hospitals and was registered under ClinicalTrials.gov identifier: NCT00670254. Registered 1 May 2008, https://clinicaltrials.gov/ct2/show/NCT00670254 . All patients participating in the study or their legal representatives gave informed consent to participate in the study. Consent for publication: Not applicable.

References

    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10. - PubMed - PMC - DOI
    1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–247. - PubMed - PMC - DOI
    1. van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021;54(11):2450–64. - PubMed - DOI
    1. Giamarellos-Bourboulis EJ, Antonelli M, Bloos F, Kotsamidi I, Psarrakis C, Dakou K, et al. Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. EBioMedicine. 2024;109:105414. - PubMed - PMC - DOI
    1. Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020;16(1):20–31. - PubMed - DOI

LinkOut - more resources